Anticardiolipin and antinuclear antibodies in cancer patients--a case control study

J B Armas; J Dantas; D Mendonça; R Farto; M Ribeiro; G Herrero-Beaumont; J Gouveia; N J McHugh

Anticardiolipin and antinuclear antibodies in cancer patients--a case control study

J B Armas, J Dantas, D Mendonça, R Farto, M Ribeiro, G Herrero-Beaumont, J Gouveia, N J McHugh

Department of Life Sciences

Research output: Contribution to journal › Article › peer-review

27 Citations (SciVal)

Abstract

OBJECTIVE: To investigate patients with cancer for the frequency of IgG and IgM aCL and ANA in comparison to a group of age- and sex-matched controls.

METHODS: Serum levels of IgG and IgM anticardiolipin antibodies (aCL), antinuclear antibodies (ANA) and anticytoplasmic antibodies were evaluated in 145 cancer patients, including 20 patients with thromboembolic disease (TED) and compared with age- and sex-matched controls.

RESULTS: Higher levels of IgG aCL were found in patients compared to controls (p < 0.02). However, there appeared to be no difference in serum aCL levels between TED and the remaining cancer patients. No difference was found in the frequency of antinuclear and anticytoplasmic antibodies between patients and controls and the autoantibody presence in patients was usually not associated with concomitant autoimmune disease.

CONCLUSION: Apart from increased levels of non-thrombogenic associated IgG aCL, there was no evidence for significantly enhanced B cell autoreactivity in this large collection of cancer patients compared to controls.

Original language	English
Pages (from-to)	227-232
Number of pages	6
Journal	Clinical and Experimental Rheumatology
Volume	18
Issue number	2
Publication status	Published - 2000

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{27cd5269a2c14f4ead4c063d9adc0a44,

title = "Anticardiolipin and antinuclear antibodies in cancer patients--a case control study",

abstract = "OBJECTIVE: To investigate patients with cancer for the frequency of IgG and IgM aCL and ANA in comparison to a group of age- and sex-matched controls. METHODS: Serum levels of IgG and IgM anticardiolipin antibodies (aCL), antinuclear antibodies (ANA) and anticytoplasmic antibodies were evaluated in 145 cancer patients, including 20 patients with thromboembolic disease (TED) and compared with age- and sex-matched controls. RESULTS: Higher levels of IgG aCL were found in patients compared to controls (p < 0.02). However, there appeared to be no difference in serum aCL levels between TED and the remaining cancer patients. No difference was found in the frequency of antinuclear and anticytoplasmic antibodies between patients and controls and the autoantibody presence in patients was usually not associated with concomitant autoimmune disease. CONCLUSION: Apart from increased levels of non-thrombogenic associated IgG aCL, there was no evidence for significantly enhanced B cell autoreactivity in this large collection of cancer patients compared to controls. ",

author = "Armas, {J B} and J Dantas and D Mendon{\c c}a and R Farto and M Ribeiro and G Herrero-Beaumont and J Gouveia and McHugh, {N J}",

year = "2000",

language = "English",

volume = "18",

pages = "227--232",

journal = "Clinical and Experimental Rheumatology",

issn = "0392-856X",

publisher = "Clinical and Experimental Rheumatology S.A.S.",

number = "2",

}

TY - JOUR

T1 - Anticardiolipin and antinuclear antibodies in cancer patients--a case control study

AU - Armas, J B

AU - Dantas, J

AU - Mendonça, D

AU - Farto, R

AU - Ribeiro, M

AU - Herrero-Beaumont, G

AU - Gouveia, J

AU - McHugh, N J

PY - 2000

Y1 - 2000

N2 - OBJECTIVE: To investigate patients with cancer for the frequency of IgG and IgM aCL and ANA in comparison to a group of age- and sex-matched controls. METHODS: Serum levels of IgG and IgM anticardiolipin antibodies (aCL), antinuclear antibodies (ANA) and anticytoplasmic antibodies were evaluated in 145 cancer patients, including 20 patients with thromboembolic disease (TED) and compared with age- and sex-matched controls. RESULTS: Higher levels of IgG aCL were found in patients compared to controls (p < 0.02). However, there appeared to be no difference in serum aCL levels between TED and the remaining cancer patients. No difference was found in the frequency of antinuclear and anticytoplasmic antibodies between patients and controls and the autoantibody presence in patients was usually not associated with concomitant autoimmune disease. CONCLUSION: Apart from increased levels of non-thrombogenic associated IgG aCL, there was no evidence for significantly enhanced B cell autoreactivity in this large collection of cancer patients compared to controls.

AB - OBJECTIVE: To investigate patients with cancer for the frequency of IgG and IgM aCL and ANA in comparison to a group of age- and sex-matched controls. METHODS: Serum levels of IgG and IgM anticardiolipin antibodies (aCL), antinuclear antibodies (ANA) and anticytoplasmic antibodies were evaluated in 145 cancer patients, including 20 patients with thromboembolic disease (TED) and compared with age- and sex-matched controls. RESULTS: Higher levels of IgG aCL were found in patients compared to controls (p < 0.02). However, there appeared to be no difference in serum aCL levels between TED and the remaining cancer patients. No difference was found in the frequency of antinuclear and anticytoplasmic antibodies between patients and controls and the autoantibody presence in patients was usually not associated with concomitant autoimmune disease. CONCLUSION: Apart from increased levels of non-thrombogenic associated IgG aCL, there was no evidence for significantly enhanced B cell autoreactivity in this large collection of cancer patients compared to controls.

M3 - Article

C2 - 10812496

SN - 0392-856X

VL - 18

SP - 227

EP - 232

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

IS - 2

ER -

Anticardiolipin and antinuclear antibodies in cancer patients--a case control study

Abstract

UN SDGs

Fingerprint

Cite this